Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robyn J Barst

Showing results (21-30 of 137) with videos related to

Pageof 14
Sort By:
Pediatric Pulmonology|December 18, 2003
Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in childrenDeepa Rastogi, Pakkay Ngai, Robyn J Barst, et al.
Chest|March 10, 2004
Identical twins with primary pulmonary hypertension: beraprost vs epoprostenolErika Berman Rosenzweig, Kelly A Schmitt, Robert Garofano, et al.
Current Opinion in Pulmonary Medicine|April 9, 2010
Clinical worsening in trials of pulmonary arterial hypertension: results and implicationsNazzareno Galiè, Gérald Simonneau, Robyn J Barst, et al.
Chest|October 16, 2004
Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up studyDavid Langleben, Andrew M Hirsch, Eileen Shalit, et al.
Pediatric Cardiology|April 21, 2010
Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertensionRobyn J Barst, Gabriella Agnoletti, Alain Fraisse, et al.
Journal of the American College of Cardiology|June 15, 2004
Endothelin receptor antagonists in pulmonary arterial hypertensionRichard N Channick, Olivier Sitbon, Robyn J Barst, et al.
The American Journal of Cardiology|May 11, 2010
Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertensionLaura Melnick, Robyn J Barst, Cherise A Rowan, et al.
Chest|February 23, 2013
Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL RegistryRobyn J Barst, Lorinda Chung, Roham T Zamanian, et al.
Chest|June 18, 2002
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot studyRobyn J Barst, Stuart Rich, Allison Widlitz, et al.
Circulation|August 4, 2004
Outcomes in children with idiopathic pulmonary arterial hypertensionDelphine Yung, Allison C Widlitz, Erika Berman Rosenzweig, et al.
Pageof 14

Showing results (21-30 of 137) with videos related to

Sort By:
Pageof 14
Pediatric Pulmonology|December 18, 2003
Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in childrenDeepa Rastogi, Pakkay Ngai, Robyn J Barst, et al.
Chest|March 10, 2004
Identical twins with primary pulmonary hypertension: beraprost vs epoprostenolErika Berman Rosenzweig, Kelly A Schmitt, Robert Garofano, et al.
Current Opinion in Pulmonary Medicine|April 9, 2010
Clinical worsening in trials of pulmonary arterial hypertension: results and implicationsNazzareno Galiè, Gérald Simonneau, Robyn J Barst, et al.
Chest|October 16, 2004
Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up studyDavid Langleben, Andrew M Hirsch, Eileen Shalit, et al.
Pediatric Cardiology|April 21, 2010
Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertensionRobyn J Barst, Gabriella Agnoletti, Alain Fraisse, et al.
Journal of the American College of Cardiology|June 15, 2004
Endothelin receptor antagonists in pulmonary arterial hypertensionRichard N Channick, Olivier Sitbon, Robyn J Barst, et al.
The American Journal of Cardiology|May 11, 2010
Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertensionLaura Melnick, Robyn J Barst, Cherise A Rowan, et al.
Chest|February 23, 2013
Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL RegistryRobyn J Barst, Lorinda Chung, Roham T Zamanian, et al.
Chest|June 18, 2002
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot studyRobyn J Barst, Stuart Rich, Allison Widlitz, et al.
Circulation|August 4, 2004
Outcomes in children with idiopathic pulmonary arterial hypertensionDelphine Yung, Allison C Widlitz, Erika Berman Rosenzweig, et al.
Pageof 14